Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis
Konuralp Tip Dergisi · 26.06.2026 · 18 (2) · 104-109
DOI: 10.18521/ktd.1838654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Konuralp Tip Dergisi, online erschienen am 26.06.2026. Verfasst von Zehra Akşit Bozkina und 7 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Aim
BCR-ABL1–negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal disorders characterized by increased myeloid proliferation. This study retrospectively evaluated the clinical, demographic, molecular, and survival characteristics of patients with classical MPNs treated at the Hematology Outpatient Clinic, Dokuz Eylül University.Material and Methods: In this single-center retrospective analysis, data from 363 patients diagnosed between January 2012 and May 2021 were reviewed according to the 2016 WHO criteria: ET (n=230), PV (n=104), and PMF (n=29).
Results
JAK2 mutations were identified in 85.1% of PV, 65.4% of ET, and 60% of PMF cases. Thrombosis at diagnosis occurred in 18% of PV, 19.1% of ET, and 10.3% of PMF patients. Cytoreductive therapy was administered to 88.2% of patients, predominantly hydroxyurea (85.7%). Leukemic and fibrotic transformations developed in 1.6% and 14.5% of cases, respectively. Among 126 patients with thrombotic events, JAK2 positivity was significantly associated with increased thrombotic risk (p=0.0025). Thrombosis was more frequent in patients aged >65 years (p=0.0047). Ten-year overall survival (OS) rates were 81% in PV, 79% in ET, and 38% in PMF. In multivariable Cox regression, age >65 years independently predicted inferior OS (p<0.001), and leukocytosis was similarly associated with poorer outcomes (p=0.026).
Conclusion
Advanced age and JAK2 V617F mutation are key risk factors for thrombosis in classical MPNs. Hydroxyurea remains the most widely used cytoreductive therapy in clinical practice.
Zitieren
APA
Bozkina, Z. A., Yavuz, B., Özkal, S., Ündar, B., Özcan, M. A., Demirkan, F., Özsan, G. H., & Alacacıoğlu, İ. (2026). Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis. Konuralp Tip Dergisi, 18(2), 104-109. https://doi.org/10.18521/ktd.1838654
Vancouver
Bozkina ZA, Yavuz B, Özkal S, Ündar B, Özcan MA, Demirkan F, et al. Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis. Konuralp Tip Dergisi. 2026;18(2):104-109. doi:10.18521/ktd.1838654
BibTeX
@article{Bozkina2026,
author = {Bozkina, Zehra Akşit and Yavuz, Boran and Özkal, Sermin and Ündar, Bülent and Özcan, Mehmet Ali and Demirkan, Fatih and Özsan, Güner Hayri and Alacacıoğlu, İnci},
title = {Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis},
journal = {Konuralp Tip Dergisi},
year = {2026},
volume = {18},
number = {2},
pages = {104--109},
doi = {10.18521/ktd.1838654}
}
EUVIMED